Grid Therapeutics

Grid Therapeutics is a private, clinical-stage biotech focused on discovering and developing novel tumor-specific antibody therapeutics. The company has a unique platform for isolating antibodies directly from human B cells and has advanced its lead candidate, GT103, into a Phase 2 investigator-sponsored trial in non-small cell lung cancer (NSCLC) in combination with pembrolizumab. While still pre-revenue, Grid is actively building its pipeline through internal R&D and external partnerships, such as a recent collaboration with Infinimmune, positioning itself in the competitive but high-potential field of cancer immunotherapy.

Proprietary platform for rapid discovery of novel tumor-specific therapeutic antibodies directly from single human B cells.

Grid operates in the highly competitive field of cancer immunotherapy, competing with large pharma (e.g., Merck, Bristol-Myers Squibb, Roche) and numerous biotechs developing antibody therapies and combination regimens. Differentiation hinges on the novelty of its tumor antigen targets and the efficiency of its discovery platform.